10. Yoshizawa H, Chang AE, and Shu S. Cellular interactions in effector cell generation 
and tumor regression mediated by anti-CD3/interleukin-2 activated tumor-draining 
lymph node cells. Cane. Res. 1 992; 52:1 129-11 36. 
1 1 . Leo O, Foo M, Sachs DH, et al. Identification of a monoclonal antibody specific for a 
murine T3 polypeptide. Proc. Natl. Acad. Sci. 1987; 84:1374-1378. 
12. Ting C-C, Hargrove ME, and Yun YS. Augmentation by anti-T3 antibody of the 
lymphokine-activated killer cell mediated cytotoxicity. J. Immunol. 1988; 141:741-748. 
13. Anderson PM, Blazar BR, Bach FH, and Ochoa AC. Anti-CD3 + IL-2 stimulated murine 
killer cells. In vitro generation and in vivo antitumor activity. J. Immunol. 1989; 
142:1383-1394. 
1 4. Geiger JD, Wagner PD, Cameron MJ, et al. Generation of T cells reactive to the poorly 
immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous 
metastases. J. Immunother. 1993; 13:153-165. 
15. Geiger JD, Wagner PD, Shu S, and Chang AE. A novel role for autologous tumor cell 
vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. 
Surg. One. 1 992; 1 :1 99-208. 
16. Chang AE, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive 
immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in 
vitro. Cane. Res. 1993: 53:1043-1050. 
17. Berd D, Maguire HC, McCue P, and Mastrangelo MJ. Treatment of metastatic 
melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 
64 patients. J. Clin. Oncol. 1990: 8:1858-1867. 
18. Hoover HC, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy 
for human colorectal cancer: 6.5 year median follow-up of a phase III prospective 
randomized trial. J. Clin. Oncol. 1993; 1 1 :390-399. 
19. Chang AE, Cameron MJ, Fox BA and Shu S. Generation of anti-CD3/IL-2 activated, 
vaccine-primed lymph node cells for the adoptive immunotherapy of human 
malignancy. (Abst. 2924) Proc. Am. Assoc. Cancer Res. 1993: 34:490. 
20. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses 
T helper function in the generation of an antitumor response. Cell 1990; 60:397-403. 
21 . Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by 
tumor cells engineered to secrete interleukin-4. Science 1991; 254:713-716. 
22. Tepper Rl, Coffman RL, Leder P. An eosinophil-dependent mechanism for the 
antitumor effect of interleukin-4. Science 1992; 257:548-551. 
23. Strome SE, Krauss JC, Cameron MJ, et al. Immunobiologic effects of cytokine gene 
transfer of the B16-BL6 melanoma. Arch, of Otol. (in press). 
24. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of moloney murine 
leukemia virus. Nature 1981 ; 293:543-548. 
[804] 
Recombinant DNA Research, Volume 18 
